
The First and Only EZH2 Inhibitor Indicated for Patients with Relapsed or Refractory Follicular Lymphoma
Marin Xavier, MD
John Pagel, MD, PhD
The First and Only EZH2 Inhibitor Indicated for Patients with Relapsed or Refractory Follicular Lymphoma
Marin Xavier, MD
John Pagel, MD, PhD
Published
February 1, 2021
Created by